Biotech Stocks on Investors' Radar -- Nektar Therapeutics, Ophthotech, PTC Therapeutics, and Spark Therapeutics

Monday, October 16, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 16, 2017 /PRNewswire/ --

If you want a Stock Review on NKTR, OPHT, PTCT, or ONCE then come over

to and sign up for your free customized report. On Friday, October 13, 2017, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green.
Major US indices were also bullish at the close of last Friday's session. The NASDAQ Composite ended the day at 6,605.80, up 0.22%; the Dow Jones Industrial Average edged 0.13% higher, to finish at 22,871.72; and the S&P 500 closed at 2,553.17, up 0.09%. This Monday morning, looks at the performance of these four Biotechnology stocks: Nektar Therapeutics (NASDAQ: NKTR), Ophthotech Corp. (NASDAQ: OPHT), PTC Therapeutics Inc. (NASDAQ: PTCT), and Spark Therapeutics Inc. (NASDAQ: ONCE). This morning's free research reports on the aforesaid equities can be accessed upon registration on at:

Nektar Therapeutics 

On Friday, shares in San Francisco, California headquartered Nektar Therapeutics recorded a trading volume of 710,048 shares. The stock ended the session 0.78% higher at $23.20. The Company's shares have gained 12.29% over the previous three months, 44.28% in the past twelve months, and 89.08% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.15% and 25.06%, respectively. Moreover, shares of Nektar Therapeutics, which develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the US, have a Relative Strength Index (RSI) of 53.28. Visit us today and download your complete report on NKTR for free at:


New York headquartered Ophthotech Corp.'s stock closed the day 1.54% higher at $2.63 with a total trading volume of 463,354 shares. The Company's shares have advanced 5.62% in the past month. The stock is trading below its 50-day moving average by 3.40%. Additionally, shares of Ophthotech, which develops novel therapeutics to treat diseases of the back of the eye, have an RSI of 47.58. The complimentary research report on OPHT can be accessed at:

PTC Therapeutics 

Shares in South Plainfield, New Jersey headquartered PTC Therapeutics Inc. recorded a trading volume of 529,192 shares. The stock ended last Friday's trading session 0.17% higher at $17.86. The Company's shares have advanced 33.18% in the past twelve months and 63.70% on an YTD basis. The stock is trading above its 200-day moving average by 17.95%. Furthermore, shares of PTC Therapeutics, which focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes, have an RSI of 44.10.

On October 09th, 2017, research firm JP Morgan downgraded the Company's stock rating from 'Neutral' to 'Underweight'. Register for free on and download the research report on PTCT at:

Spark Therapeutics 

Philadelphia, Pennsylvania headquartered Spark Therapeutics Inc.'s stock finished Friday's session 2.29% lower at $84.23 with a total trading volume of 1.94 million shares, which was above their three months average volume of 512.07 thousand shares. The Company's shares have advanced 41.90% over the previous three months, 48.19% in the past twelve months, and 68.80% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 2.31% and 30.73%, respectively. Additionally, shares of Spark Therapeutics, which focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases, have an RSI of 46.91.

On October 13th, 2017, research firm Stifel reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $92 a share to $101 a share. Get free access to your research report on ONCE at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store